Switzerland is a pharmaceutical giant ... a producer could simply exit the Swiss market. That's why pharmaceutical companies have long demanded that they be compensated for their compulsory ...

Even with these fears allayed, why should every pharmaceutical marketer understand ... is a ZS Business Consultant based in Zurich, Switzerland, and is specialised in digital and social media ...

Swiss pharma giant Roche is refocusing its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.

Why pharma stocks can be more volatile ... phase 1 clinical trial with MDMA and LSD in the fourth quarter in Basel, Switzerland. Meanwhile, Compass Pathways is developing a synthetic version ...

This explains why Switzerland is now launching ... And Switzerland wants to exploit this potential. As for the pharmaceutical industry – Switzerland’s largest exporter – it has saved only ...

Already five-six banks have been ahead of the Fed, especially Canada and ECB, Switzerland ... They have done well as well.

Senator Bernie Sanders grilled the Novo Nordisk CEO today on Capitol Hill for charging 9x for products in the United States vs the products in Germany. Trump tax plans could exempt 93 million ...

But hang on a minute, why on earth should Switzerland, which never joined ... industry has developed very strongly," he says. "Also in pharmaceuticals, the chemical industry is really top notch ...

Switzerland and Kenya have been fostering ... Swiss companies have been in Kenya for many years. Recently, Swiss pharmaceutical businesses have shown an increased interest in the Kenyan market.

Here's why healthcare in the United States is so expensive, but the quality of care in the U.S. still ranks low among ...

That is why SCHOTT Pharma designs solutions grounded in science ... developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for ...

Price controls will deprive the pharmaceutical industry of revenue that could be invested in research and development. But the caps will also dissuade investors from funding drug discovery.